Necitumumab
EGFR Inhibitor
DB09559
Approved Indication
Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.
1
Targets
0
Resistance Mutations
4
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Necitumumab is an EGFR antagonist that functions by binding to epidermal growth factor receptor (EGFR) and preventing binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation.
Details
DrugBank ID
DB09559 ↗
Approval Date
2015-11-24
Molecular Weight
— g/mol
Drug Class
EGFR Inhibitor
ATC Codes
L01XC22
Synonyms
—
Drug References (DrugBank)